In‐patient benzodiazepine withdrawal: comparison of fixed and symptom‐triggered taper methods
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Fixed and symptom‐triggered taper methods during in‐patient benzodiazepine withdrawal treatment were compared using a randomized controlled design. Forty‐four benzodiazepine users seeking in‐patient withdrawal treatment at two substance use treatment clinics in Adelaide, Australia were recruited. Measurements included the Severity of Dependence Scale and the SF–36. A scale comprising six items from the Clinical Institute Withdrawal Assessment Scale—Benzodiazepines (CIWA‐B) was used to measure withdrawal symptoms. Participants were randomized to receive a fixed diazepam tapering regime or diazepam only in response to withdrawal symptoms (symptom‐triggered group). Results showed that there were no significant differences between treatment groups in terms of withdrawal severity, duration of in‐patient treatment, amount of diazepam administered, treatment attrition and benzodiazepine use at follow‐up. Both groups showed a reduction in benzodiazepine dosage of 86% over the first 8 days which was maintained at 1 month post‐discharge. Although there were improvements in some subscales of the SF–36 between baseline and follow‐up, values were significantly below age‐matched norms at both time‐points. This study showed that benzodiazepine users entering treatment have relatively poor health and that symptom‐triggered taper methods incorporating flexible dosing and flexible treatment duration are as effective as fixed dose taper methods for in‐patient benzodiazepine withdrawal treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170
Benzodiazepine withdrawal: outcome in 50 patients
ASHTON, H. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb01529.x · Cited by 160
Cited by
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In high-dose users, reducing to a ‘therapeutic’ benzodiazepine dose level may be an appropriate first aim (McGregor et al., 2003; Vorma et al., 2002, 2003) (Ib), because of the high relapse or drop-out rates with detoxification.”
BackgroundWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[43-50] Many ed as a ‘pure’ antagonist, subsequent work in both other studies were excluded for a variety of reasons, animals and humans has suggested that flumazenil is including inappropriate outcome measures, setting a mixed agonist/antagonist, depending partly on and selection of participants.[51-73] Several of th…”
ResultBenzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Metadata
- Authors
- MCGREGOR, C., MACHIN, A., & WHITE, J. M.
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2003-06
- Volume
- 22
- Issue
- 2
- Pages
- 175-180
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- OpenAlex
- W2012373416
- Cited by
- 49
- References
- 3
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In‐patient benzodiazepine withdrawal: comparison of fixed and symptom‐triggered taper methods. https://app.cochat.ai/papers/10.1080/09595230100100615
- The paper
- MCGREGOR, C., MACHIN, A., & WHITE, J. M. (2003). In‐patient benzodiazepine withdrawal: comparison of fixed and symptom‐triggered taper methods. Drug and Alcohol Review. https://doi.org/10.1080/09595230100100615
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.